Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers.


Journal

International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481

Informations de publication

Date de publication:
2022
Historique:
received: 21 02 2022
accepted: 09 06 2022
entrez: 1 7 2022
pubmed: 2 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

Body plethysmography is a fundamental method for the assessment of static lung volumes. Although equipment is provided by several manufacturers, there are no established cross-vendor tools for quality control. In the process of quality control and analysis of data on hyperinflation from the large COPD cohort COSYCONET, hints appeared that plethysmographs of different vendors might yield different values for static lung volumes. Functional residual capacity (FRC) differed about 0.67 litres between plethysmographs of the manufacturer Vyaire and Ganshorn. Absolute differences of residual lung volume (RV) and total lung capacity (TLC) were similar. It appears undeniable that differences of this magnitude have an impact on clinical interpretation. Thus, device harmonization seems to be required.

Identifiants

pubmed: 35774592
doi: 10.2147/COPD.S363493
pii: 363493
pmc: PMC9239195
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1477-1482

Informations de copyright

© 2022 Alter et al.

Déclaration de conflit d'intérêts

Peter Alter declares no relevant competing interests. Jan Orszag declares no relevant competing interests. Emiel F. M. Wouters declares no relevant competing interests. Claus F. Vogelmeier declares grants or contracts to his institution from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Menarini, Novartis, and Nuvaira, MedUpdate, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Menarini, and Novartis, all of which are outside the scope of the submitted work. Rudolf A. Jörres declares no relevant competing interests.

Références

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555
pubmed: 30197511
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Respir Med. 2016 May;114:27-37
pubmed: 27109808
Eur Respir J. 2017 Mar 6;49(3):
pubmed: 28182564
Respirology. 2013 Jan;18(1):170-8
pubmed: 23279785
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1083-91
pubmed: 19745204
ERJ Open Res. 2020 Jul 27;6(3):
pubmed: 32743009
Respir Med. 2011 Jul;105(7):959-71
pubmed: 21356587

Auteurs

Peter Alter (P)

Department of Medicine, Pulmonary and Critical Care Medicine, Philipps-University of Marburg (UMR), Germany, Member of the German Center for Lung Research (DZL), Marburg, Germany.

Jan Orszag (J)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.

Emiel F M Wouters (EFM)

Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, Netherlands.
Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.

Claus F Vogelmeier (CF)

Department of Medicine, Pulmonary and Critical Care Medicine, Philipps-University of Marburg (UMR), Germany, Member of the German Center for Lung Research (DZL), Marburg, Germany.

Rudolf A Jörres (RA)

Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH